Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{196057,
        author = {Dr. Minal Narkhede and Chetana Shimpi and Dr Shilpa Badhe},
        title = {Formulation & Clinical Evaluation of Polyherbal Capsule as Adjuvant to NSAID’s in Post Ksharsutra Pain Management.},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {12},
        number = {11},
        pages = {3540-3545},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=196057},
        abstract = {Ksharsutra therapy is a widely accepted treatment modality for fistula-in-ano (Bhagandara), but post-procedural pain remains a significant clinical concern affecting patient comfort and compliance. Conventional management with non-steroidal anti-inflammatory drugs such as Diclofenac provides effective pain relief; however, prolonged use is associated with various adverse effects. The present study was undertaken to formulate a polyherbal capsule and evaluate its efficacy as an adjuvant to NSAIDs in the management of post-Ksharsutra pain. A randomized, open-label, controlled clinical study was conducted on patients undergoing Ksharsutra therapy, who were divided into two groups: a control group receiving NSAIDs alone and a trial group receiving NSAIDs along with a polyherbal capsule (500 mg twice daily). The formulation comprised extracts of Curcuma longa, Commiphora mukul, and Boswellia serrata along with powders of Zingiber officinale, Vitex negundo, Triphala, Ricinus communis, and Cynodon dactyl. Preformulation and post-formulation evaluation confirmed that the capsules possessed acceptable physicochemical and pharmaceutical properties. Pain was assessed using the Visual Analogue Scale (VAS) at regular intervals. The results demonstrated a statistically significant reduction in pain scores in the trial group compared to the control group (p < 0.05), along with a reduction in NSAID consumption, indicating an NSAID-sparing effect. Improved wound healing and absence of significant adverse effects were also observed in the trial group. In conclusion, the polyherbal capsule was found to be a safe and effective adjuvant to NSAIDs in reducing post-Ksharsutra pain and minimizing associated drug-related side effects},
        keywords = {Ksharsutra therapy, Polyherbal formulation, Post-operative pain, NSAIDs, Diclofenac, Visual Analogue Scale (VAS), Fistula-in-ano, Adjuvant therapy, Anti-inflammatory, Analgesic},
        month = {April},
        }